101 related articles for article (PubMed ID: 17964978)
1. [Trastuzumab and blood-brain barrier].
Platini C
Bull Cancer; 2007 Oct; 94(10):857-9. PubMed ID: 17964978
[TBL] [Abstract][Full Text] [Related]
2. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
[TBL] [Abstract][Full Text] [Related]
3. Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
Altundag K; Altundag O; Atik MA; Morandi P; Gunduz M
Breast; 2005 Oct; 14(5):425. PubMed ID: 16216749
[No Abstract] [Full Text] [Related]
4. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
5. Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.
Bulut N; Harputluoglu H; Dizdar O; Altundag K
J Neurooncol; 2008 Jan; 86(2):241. PubMed ID: 17612792
[No Abstract] [Full Text] [Related]
6. Intrathecal trastuzumab: dose matters.
Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
[No Abstract] [Full Text] [Related]
7. A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys.
Braen AP; Perron J; Tellier P; Catala AR; Kolaitis G; Geng W
Int J Toxicol; 2010; 29(3):259-67. PubMed ID: 20448258
[TBL] [Abstract][Full Text] [Related]
8. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
Platini C; Long J; Walter S
Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
[No Abstract] [Full Text] [Related]
9. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
[TBL] [Abstract][Full Text] [Related]
10. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
Lai R; Dang CT; Malkin MG; Abrey LE
Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system metastases in breast cancer patients administered trastuzumab.
Duchnowska R; Szczylik C
Cancer Treat Rev; 2005 Jun; 31(4):312-8. PubMed ID: 15979804
[TBL] [Abstract][Full Text] [Related]
12. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
Baculi RH; Suki S; Nisbett J; Leeds N; Groves M
J Clin Oncol; 2001 Jul; 19(13):3297-8. PubMed ID: 11432901
[No Abstract] [Full Text] [Related]
13. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
14. Treatment of brain metastases in patients with HER2+ breast cancer.
Bravo Marques JM
Adv Ther; 2009 Jul; 26 Suppl 1():S18-26. PubMed ID: 19669638
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab in CNS progressive metastatic breast cancer.
Tosoni A; Franceschi E; Esposti RD; Brandes AA
Future Oncol; 2007 Aug; 3(4):367-9. PubMed ID: 17661709
[No Abstract] [Full Text] [Related]
16. Correction: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
Pestalozzi BC
J Clin Oncol; 2001 Oct; 19(20):4091. PubMed ID: 11600616
[No Abstract] [Full Text] [Related]
17. Progressive central nervous system metastases in responder patients for outside central nervous system metastases on trastuzumab-based therapy--report of two cases of refractory breast cancer.
Okita R; Saeki T; Takashima S; Aogi K; Ohsumi S
Hiroshima J Med Sci; 2005 Mar; 54(1):35-8. PubMed ID: 15847063
[TBL] [Abstract][Full Text] [Related]
18. Brain metastases in patients receiving trastuzumab for breast cancer.
Errante D; Bernardi D; Bianco A; Salvagno L
Neurol Sci; 2007 Mar; 28(1):52-3. PubMed ID: 17385098
[No Abstract] [Full Text] [Related]
19. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
Niwińska A; Tacikowska M; Murawska M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
[TBL] [Abstract][Full Text] [Related]
20. Brain metastases in patients receiving trastuzumab for breast cancer.
Salmaggi A; Silvani A; Boiardi A
Neurol Sci; 2007 Mar; 28(1):1. PubMed ID: 17385088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
